Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Kohl's Corporation (KSS) Price & Performance

Abeona Therapeutics IncTrade
Kohl's CorporationTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Kohl's Corporation — how do they compare? Abeona Therapeutics Inc trades at $7.37 (market cap $421.19M), while Kohl's Corporation trades at $18.74 (market cap $2.10B). The key difference: Kohl's Corporation is far larger — about 5× Abeona Therapeutics Inc's market cap, and Kohl's Corporation pays a 2.7% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.

ABEOKSS
Market Cap
$421.19M$2.10B
Sector
HealthConsumer Cyclical
52-Week High
$7.45$24.71
52-Week Low
$4.17$11.72
Enterprise Value
$276.10M$8.20B
Dividend Yield
2.7%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.

The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.

Kohl's Corporation

Kohl's stock trades at $19.04, down 1.35% with a bullish technical signal despite recent weakness. The company shows improving fundamentals with three consecutive earnings beats and positive cash flow projections for 2026. Valuation metrics appear attractive with P/E of 7.77 and P/B of 0.52, while recent management changes and proprietary brand growth provide operational momentum.

Kohl's presents a turnaround opportunity with undervalued metrics and improving operational execution, though declining revenue and thin margins pose significant challenges. Analyst consensus remains cautious with a $16.75 price target below current levels, reflecting concerns about sustained growth in a competitive retail environment.

Returns comparison

Trailing returns across standard periods

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Kohl's Corporation

Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.

Read more on KSS